Last reviewed · How we verify
PEP07
At a glance
| Generic name | PEP07 |
|---|---|
| Sponsor | PharmaEngine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer (PHASE1)
- A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEP07 CI brief — competitive landscape report
- PEP07 updates RSS · CI watch RSS
- PharmaEngine portfolio CI